OKffbcr 1-2, 1994, Oats Management Report -- Page 14 
£ 
1 
it TV - P 
See 14 
Protocol 
Status 
1? 1 
1 = 2 I 
a * u. • 
I 1 
Is 1 
1 1 
S=fc 
a z • 
I 1 
12 & 
a. u. 0 
IS 1 
1=2 i 
a. z u. • 
I 1 ! 
I = | 
I 1 
1= & 
O. Z « 
• Deaths 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
Adverse 
Effects 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
Problem 
Associated 
With Gene 
Transfer 
< 
z 
« 
z 
< 
z 
< 
z 
« 
z 
< 
z 
< 
Evidence Of 
Biological 
Activity 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
In Vivo Evidence Of 
Gene Transfer And 
Expression In 
Target Celts 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
< 
z 
Patients 
Entered On 
Study 
o 
o 
< 
z 
0 
0 
0 
0 i 
ill 
IIS 
42 
(M/F) 
21 vector 
21 vector/ 
♦ cispletln 
V 
•0 
A 
•n x 
1*. 
00 X 
>o X 
rg w 
0 X 
0 
'■v 
O X 
rg w 
si 
n 
A- 
o 
t 
u 
i 
M 
o’ a 
-A 
U 
V> P- 
0 
0 
2 
to 
i. 
> O 
8 
I 
Vector Construct 
Packaging Cell Line 
{Delivery Vehicle) 
K) 3 
* I 
s 1 
S R 1 
3 5 
t i 
O K. L. 
Z V 
a a. w 
TFG-hlL-12-Meo 
psl-crlp 
(Retrovirus) 
HFG-hu-GM-CSF 
psl -crip 
(Retrovirus) 
u 
! I 
f! }! 
11 - 1 ! 
sil 5 Si 
x x a w< 
i 5 
>x *v 
1 8 8 
Dates of 
T reetaent : 
(1) First Patient 
<2) Most Recent 
Patient 
< 
z 
< 
z 
< 
Z 
< 
z 
< 
z 
< 
z 
< 
z 
\ 
u 
u « 
Z 
P- V 
I 
• 
m 
u *8 
1 1 
- (? 
U S « Ph 
— w « JA 
R it£8 
*- v U O Z 
• 
• 
** 
1 ! 
u 
V. 
8 
« 
• 
« 
0 t 
V CD 
0 
8 
>x 
8 
• 
O 
lass 
* $ ; e 
RAC/6-10-94 
NIH/Pending 
FDA/Pending 
? ? i 
« ^ ^ 
u z < 
< — o 
QC Z 
2 f 
t 1 
•o a 
X V V 
o z < 
< — a 
oc z u- 
2 I | 
— ? 1 
•0 • 4* a. 
-hs O V. 
* O > < 
— < it O 
z w at u_ 
2 8? 
? 1 1 
0 a. q. 
-x. '•v -«o 
u z < 
< — 0 
QC Z U. 
2 8 
? 1 
o» a. 
•"x 
<J z < 
< — 0 
ac z u. 
2 8 
T 1 
O O. 
U X < 
2 * £ 
6 
i i 
“■ z 
t 
6 
« 
t- 
» i 
s e 
*V. 
~m 
• 
-»* u 
i i 
vC 
a» 
I 
• 
t r 
m a. 
s = 
s 
1 
z 
i l 
vt *» 
2 
1 
V* Z 
• 
S 8 
5 * 
u. •» 
'-x • 
• 3 
• 4-» 
* f 
5 i 
z > 
O | 
L. 
• 
i = *5 
" to 
£ 08 = 
0 u«z 
m S 
! ! 
& ? 
1 1 
2 t 
? 1 
8 8 
2 t 
8 
8 
2 
» ! 
8 8 
2 t 
? ! 
8 8 
2 & 
§ 
S 
2 
(A 
s ; 
1521 ] 
